

Dear editors of World Journal of Clinical Cases ,

We are very honored to hear from you and extremely appreciated for the precious revision opportunity you offered. Your efforts enable the improvement of this manuscript. All the concerns raised by the reviewer had been immediately discussed in our group. Modifications had been made accordingly.

Hereby, with your permission, we would like to respond to the each concern from the three reviewers in detail.

Reviewer #1 (03001816):

- 1. The writing requires significant editing for grammar and word usage. Also, I'm not comfortable with MSS CRC being called a "subset" of MSI. Maybe the terminology differs in different countries, but here the two are considered separate entities.*

Answers: Thank you for your suggestions! You offer a precious opportunity for this manuscript. We really appreciate your suggestions. The writing has been edited for both grammar and word usage. We try to revise the MSI section in a more agreeable way as follow: MSI, also refers to mismatch repair (MMR), has been one of the key genomic markers in CRC. Based on its genomic status, patients can be stratified as MSI-High (MSI-H), MSI-Low (MSI-L) and microsatellite stable (MSS) CRC, similarly to the classification of MMR-deficient (dMMR) and MMR-proficient (pMMR).

Reviewer #2 (02505493):

- 2. This review manuscript aims to present and discuss the beneficial effects of antiviral therapy to colorectal cancer metastasized to liver. This work is of potential interest for specialized oncologists. However, the manuscript cannot be accepted for publication in its present form, since there are some points requiring correction or revision, as follows. 1. The text requires extensive linguistic revision.*

There are several grammar/syntax/typo errors (i.e., page 3: line 6; page 3: line 23; page 5: line 1; page 7: line 6). 2. In most cases, literature is out of date. It is better to include more recent studies. In addition, several references need corrections (i.e. 1, 8, 15, 20, 21).

Answers: Thank you for the comments. We deeply appreciate your time and efforts in this manuscript. Grammar/syntax/typo errors you mentioned in this manuscript has been revised accordingly (page 3: line 6; page 3: line 23; page 5: line 1; page 7: line 6)). Other potential errors have also been language edited. Given the problem of “out of data”, we further extend the literature research and update the reference. For example, Huang G, Li P, Lau W, et al. Antiviral therapy reduces hepatocellular carcinoma recurrence in patients with low HBV-DNA levels: a randomized controlled trial. *Ann Surg* 2018; doi: 10.1097/SLA.0000000000002727. Zhang Y M, Liu G M. Comment on “Antiviral Treatment for Postcurative Hepatitis B Virus-related Hepatocellular Carcinoma”[J]. *Annals of surgery*, 2019, 269(6): e80-e81. Moreover, the wrong format of references was corrected.

Reviewer #3 (03005388):

3. *I think there should be more references to support the hypotheses in “Absent liver metastasis in CRC with HBV/HCV” section, the second paragraph of “Potential mechanistic clues” section, and the first paragraph line 1 to line 4 of “Antiviral therapy and immune system” section.*

Answers: Thank you for your suggestions! More references have been added in “Absent liver metastasis in CRC with HBV/HCV” section, the second paragraph of “Potential mechanistic clues” section and the first paragraph of “Antiviral therapy and immune system” to each discussion, respectively.

Chaoran Yu

M.D., Ph.D., Fudan University Shanghai Cancer Center, Fudan University;
Shanghai 200025, P.R.China; phone: +86-21-64458887; FAX:
+86-21-64458887; E-mail: chaoran_yu@sjtu.edu.cn; chaoran_yu@yeah.net.